Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Early Pipeline Case Study

- PMLiVE

UK COVID-19 vaccination drive hit with supply delays over the coming weeks

Weekly vaccine supplies face a 'significant reduction' from 29 March

- PMLiVE

A new era for UK-Japanese scientific research relations

Japan’s biopharmaceutical firms contributed $62.4bn, or 1.3% of GDP, to the country’s economic output in 2019

Out Of Office: The New Normal for Ad Agencies

Covid has made working from home mandatory for most agencies. Life after lockdown may never be the same.

Life Healthcare Communications

- PMLiVE

GSK and Medicago initiate late-stage COVID-19 vaccine study

Plant-based, adjuvanted vaccine candidate received FDA fast track designation in February

- PMLiVE

Create Health announces relaunch under new creativity banner

Healthcare agency announces relaunch 12 months after management buy-out

- PMLiVE

EU announces ‘top-up’ of ten million Pfizer/BioNTech vaccines in Q2

Brings total number of doses of the vaccine to be delivered in Q2 to over 200 million

- PMLiVE

Benefits of AZ COVID-19 vaccine ‘continue’ to outweigh risks, says EMA’s executive director

EU regulator is expected to publish findings from its investigation on Thursday

- PMLiVE

Edging towards success

Evolution tells us to look for small advantages, not big leaps

- PMLiVE

A Stellar Start to 2021 for Lucid Group

It’s been a stellar start to 2021 for Lucid Group, which has welcomed 38 new starters into the company since the beginning of the year. These include 15 Client Services...

Lucid Group Communications Limited

- PMLiVE

Sanofi and Translate Bio launch phase 1/2 trial of mRNA-based COVID-19 vaccine

Vaccine candidate induced high antibody levels in preclinical studies

- PMLiVE

Lilly to expand donanemab study in a bid for approval in Alzheimer’s disease

Lilly revealed expanded findings from phase 2 TRAILBLAZER-ALZ study this week

- PMLiVE

AstraZeneca to supply US government with 500,000 additional doses of its COVID-19 antibody

AZD7442 is a long-acting antibody combination that could help to prevent and treat COVID-19

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links